Across TCGA pan-cancer cohorts, SMYD3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SMYD3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SMYD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SMYD3 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

COAD, CCRCC, and LSCC are the cancer types where SMYD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMYD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.447	<.001	8	view →
CCRCC	Male	All	+0.144	<.001	6	view →
LSCC	Female	All	−0.274	<.001	4	view →
LUAD	All	All	+0.154	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SMYD3 RNA expression & survival · all SMYD3 data types